EXT Life Sciences Announces New Biotech Treatment that Tackles Root Cause of Graying Hair
Breakthrough Comes as Scientific Community Intensifies Anti-Aging Research
“The preservation of good health and youthful appearance well into old age is critical to the EXT mission. Given the dramatic growth of an aging global population, our research presents a transformative development for society while also introducing business opportunities for the cosmeceutical and medical fields,” said Dr. Terlecky.
EXT’s targeted catalase technology, called CatSKL(TM), reintroduces catalase into the peroxisome (a compartment) of aged cells to reestablish the balance of pro- and anti-oxidants and has already earned patent protection in several countries. Dr. Terlecky’s extensively published body of research validates the importance of maintaining the balance between catalase and the oxidants it neutralizes, not only in the follicles of graying hair, which is deemed the first visible sign of aging deterioration, but also in cells corrupted by diseases associated with the aging process such as diabetes, arthritis, heart disease, stroke, Alzheimer’s and Parkinson’s.
EXT’s announcement occurs as the scientific community deepens its research into aging issues. In a recently published scientific report, researchers at
“EXT not only understands the process that turns hair gray but offers an antidote to prevent or reverse the gray. We are ahead of the game in terms of nearing the point where we can act on our research and take a product to market,” affirms Dr. Terlecky.
TechTown is an urban community of entrepreneurs, investors, mentors and corporate partners creating an internationally influential village in
About EXT Life Sciences, Inc.
EXT is a